Glenmede Trust Co. NA Boosts Position in Waters Corporation $WAT

Glenmede Trust Co. NA raised its position in Waters Corporation (NYSE:WAT) by 21.4% during the 1st quarter, Holdings Channel reports. The firm owned 52,658 shares of the medical instruments supplier’s stock after acquiring an additional 9,293 shares during the quarter. Glenmede Trust Co. NA’s holdings in Waters were worth $15,682,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Waters by 112.9% during the 4th quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after buying an additional 673 shares during the last quarter. Integrated Wealth Concepts LLC grew its stake in Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Waters by 3.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after acquiring an additional 6,976 shares during the last quarter. Empowered Funds LLC increased its holdings in Waters by 16.6% during the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock valued at $415,000 after acquiring an additional 160 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in Waters during the 2nd quarter valued at about $232,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on WAT shares. Wolfe Research began coverage on shares of Waters in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price target on the stock. Wall Street Zen cut shares of Waters from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. UBS Group lifted their price objective on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Piper Sandler initiated coverage on Waters in a research note on Thursday, June 11th. They issued a “neutral” rating and a $400.00 target price on the stock. Finally, Bank of America increased their target price on Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $401.60.

Waters Price Performance

NYSE:WAT opened at $377.75 on Friday. The firm has a market cap of $37.09 billion, a price-to-earnings ratio of 48.00, a price-to-earnings-growth ratio of 2.28 and a beta of 1.20. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The company’s 50-day moving average is $369.30 and its two-hundred day moving average is $345.48. Waters Corporation has a 12-month low of $275.05 and a 12-month high of $414.15.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.39. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The firm’s revenue for the quarter was up 91.4% compared to the same quarter last year. During the same period last year, the company earned $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Research analysts expect that Waters Corporation will post 14.51 EPS for the current year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.